http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
에토석시미드의 HPLC 분석법 및 한국인에서의 약동학적 특징
배정우(Jung-Woo Bae),김지홍(Ji-Hong Kim),양상인(Sang-In Yang),김현경(Hyun-Kyung Kim),장춘곤(Choon-Gon Jang),한혜원(Hye-Won Han),박영서(Young-Seo Park),손의동(Uy-Dong Sohn),이석용(Seok-Yong Lee) 대한약학회 2003 약학회지 Vol.47 No.6
Ethosuximide is an oral anticonvulsantic agent used in the first choice anti-absence seizure drug. The purpose of this study was to assess the pharmacokinetic profile of the ethosuximide in healthy Korean volunteers and to develop the efficient assay method of ethosuximide in human plasma. The pharmacokinetics of ethosuximide administered orally was evaluated after a dose of 500 mg. Ethosuximide was assayed from plasma by a specific HPLC method reading absorbance at 195 nm. AUC was 1222±160 μg/ml·hr, Cmax 14.21±1.74 μg/ml, Tmax 1.06±0.62 hr and half-life 77.83±12.46 hr. The half-life in Korean was longer than, in Caucasian (53~56 hr).
Acarbose 제제의 약력학적 평가 및 생물학적동등성 시험법에 대한 연구
배정우,장춘곤,이석용,Bae, Jung-Woo,Jang, Choon-Gon,Lee, Seok-Yong 대한약학회 2007 약학회지 Vol.51 No.6
Arcabose is a competitive inhibitor of the intestinal ${\alpha}$-glucosidases and reduces the postprandial digestion and absorption of carbohydrate and disaccharides. Due to its negligible oral absorption, measuring drug concentration in the plasma is impractical. Thus, the common pharmacokinetic study is not available to determine the bioequivalence of the generic acarbose preparations. The aim of this study is the establishment of pharmacodynamic assessment method for the bioequivalence test of the generic acarbose preparations. Placebo-controlled cross-over ($3{\times}3$) clinical study was conducted in 23 healthy volunteers. Volunteers received a single oral dose of placebo, reference drug ($Glucoby^{(R)}$ 100 mg, Lot # D043) or test drug ($Glucoby^{(R)}$ 100 mg, Lot # E005) just before breakfast, then blood samples for evaluation of serum glucose and insulin levels were taken during for 4 hours. $C_{max},\;AUC_{0-2},\;AUC_{0-4},\;{\Delta}C_{max},\;{\Delta}AUC_{0-2}\;and\;{\Delta}AUC_{0-4}$ of the postprandial plasma glucose level significantly decreased when a single dose of acarbose 100 mg preparations was administered. However, any significant difference was not detected between the groups taken the reference drug and the test drug. These results proposed that the pharmacodynamic protocols of this study is suitable to use for bioequivalence test of acarbose preparations. On the basis of the results of this study and the data of literature on this subject, the standard protocols of bioequivalence study of acarbose preparation are proposed.
프로카인아미드의 HPLC 분석법 및 한국인에서의 약동학적 특징
배정우(Jung-woo Bae),김현경(Hyun-Kyung Kim),양상인(Sang-In Yang),김지홍(Ji-Hong Kim),김경혜(Kyung-Hye Kim),장춘곤(Choon-Gon Jang),박영서(Young-Seo Park),손의동(Uy-Dong Sohn),이석용(Seok-Yong Lee) 大韓藥學會 2005 약학회지 Vol.49 No.3
Procainamide is the drug of second choice (after lidocaine) in most coronary care units for the treatment of sustained ventricular arrhythmias associated with acute myocardial infarction. The purpose of this study was to develop the efficient assay method of procainamide in human plasma and to assess the pharmacokinetic profile of procainamide in healthy Korean volunteers. The pharmacokinetics of procainamide administered orally was evaluated after a dose of 250 mg. Procainamide in plasma was assayed using a specific HPLC method with UV absorbance at 275nm. AUC was 4.58±0.90 μg/ml.hr, Cmax 1.34±0.39 μg/ml, Tmax 1.06±0.34 hr and half-life 3.07±0.34 hr. Tmax was slightly shorter than that in Caucasian (1~2hr), whereas the half-life was similar to that in Caucasian (2.5~4.1 hr).
와파린의 HPLC 분석법 및 한국인에서의 약동학적 특징
배정우,김현경,양상인,김지홍,김경혜,장춘곤,박영서,손의동,이석용,Bae, Jung-Woo,Kim, Hyun-Kyung,Yang, Sang-In,Kim, Ji-Hong,Kim, Kyung-Hye,Jang, Choon-Gon,Park, Young-Seo,Sohn, Uy-Dong 대한약학회 2005 약학회지 Vol.49 No.2
Warfarin is a widely used oral anticoagulant agent used to treat thromboembolic disease. The purpose of this study was to develop the efficient assay method of warfarin sodium i n human plasma and to assess the pharmacokinetic profile of the warfarin in healthy Korean volunteers. The pharmacokinetics of warfarin administered orally was evaluated after a dose of 10 mg. Warfarin in plasma was assayed using a specific HPLC method with UV absorbance at 304 nm. AUC was 46.33${\pm}9.95{\mu}g/ml.hr$, $C_{max}$ $1.22{\pm}0.22{\mu}g/ml, $T_{max}$$2.50{\pm}1.41$ hr and half-life $43.49{\pm}4.33$ hr. $T_{max}$ was slightly shorter than that in Caucasian (3~9 hr), whereas the half-life was longer than that in Caucasian (10~45 hr, mean: 36 hr). These results suggest that warfarin may have a longer duration in Korean than in Caucasian.